Biomea Fusion Inc (BMEA)
10.52
+0.06
(+0.57%)
USD |
NASDAQ |
May 31, 16:00
10.52
0.00 (0.00%)
Pre-Market: 20:00
Biomea Fusion Cash from Financing (Quarterly): 0.116M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.116M |
| December 31, 2023 | 0.622M |
| September 30, 2023 | 0.138M |
| June 30, 2023 | 162.84M |
| March 31, 2023 | 0.201M |
| December 31, 2022 | 0.49M |
| September 30, 2022 | 0.40M |
| June 30, 2022 | 0.318M |
| March 31, 2022 | 0.031M |
| Date | Value |
|---|---|
| December 31, 2021 | 0.246M |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 152.94M |
| March 31, 2021 | -0.003M |
| December 31, 2020 | 56.39M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 9.528M |
| March 31, 2020 | 0.05M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.003M
Minimum
Mar 2021
162.84M
Maximum
Jun 2023
22.61M
Average
0.246M
Median
Dec 2021
Cash from Financing (Quarterly) Benchmarks
| Poseida Therapeutics Inc | -0.043M |
| Cartesian Therapeutics Inc | 43.03M |
| BioXcel Therapeutics Inc | 26.63M |
| NovaBay Pharmaceuticals Inc | -0.597M |
| Palatin Technologies Inc | 9.136M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -32.03M |
| Cash from Investing (Quarterly) | -0.035M |
| Free Cash Flow | -105.08M |
| Free Cash Flow Per Share (Quarterly) | -0.8934 |
| Free Cash Flow Yield | -28.00% |